Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the
company will make presentations at the following upcoming events.
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral
Vascular Disease (ATVB|PVD) 2016 Scientific Sessions – Nashville,
May 5-7, 2016
May 6, 11:00 a.m. CDT – Stacey Melquist, Ph.D., Arrowhead senior
scientist, and coauthors, will deliver a poster presentation titled, “Lipoprotein(a)
targeting with RNAi delivery platforms in transgenic mice and cynomolgus
monkeys” (Presentation Number 428)
IBC’s 18th Annual TIDES: Oligonucleotide and
Peptide Therapeutics – Long Beach, California, May 9-12, 2016
May 9, 1:30 p.m. PDT – David Rozema, Ph.D., Arrowhead vice
president of chemistry will deliver an oral presentation titled, “Protease-sensitive
endosomal escape for delivery of siRNA in vivo”
May 9, 1:30 p.m. PDT – Qingguo Tian, Ph.D., Arrowhead
bioanalytical project manager will deliver an oral presentation titled, “Sensitive
and specific quantification of oligonucleotides in biological matrices
using hybridization based LC-fluorescence assays”
5th Asian Conference on Hepatitis and AIDS (ACHA) – Nanjing,
China, May 28-29, 2016
May 29, 4:50 p.m. CST (China Standard Tim) – Bruce Given, M.D.,
Arrowhead chief operating officer will deliver an oral presentation
titled, “RNAi therapeutics for chronic HBV – Animal models”
Copies of presentation materials can be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website after each presentation is delivered.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for
chronic hepatitis B virus infection, ARC-AAT for liver disease
associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary
angioedema and thromboembolic disorders, ARC-LPA for cardiovascular
disease, and ARC-HIF2 for renal cell carcinoma.
For more information please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement
of our intellectual property rights. Our most recent Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of
the important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005194/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor
Relations:
The Trout Group
Chad Rubin, 646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo
Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Pharmaceuticals, Inc.
News Provided by Acquire Media